| Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization S Cele, L Jackson, DS Khoury, K Khan, T Moyo-Gwete, H Tegally, JE San, ... Nature 602 (7898), 654-656, 2022 | 1474* | 2022 |
| T cell responses to SARS-CoV-2 spike cross-recognize Omicron R Keeton, MB Tincho, A Ngomti, R Baguma, N Benede, A Suzuki, K Khan, ... Nature 603 (7901), 488-492, 2022 | 632* | 2022 |
| SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape S Cele, F Karim, G Lustig, JE San, T Hermanus, H Tegally, J Snyman, ... Cell host & microbe 30 (2), 154-162. e5, 2022 | 227 | 2022 |
| Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y. V2 (B. 1.351) T Moyo-Gwete, M Madzivhandila, Z Makhado, F Ayres, D Mhlanga, ... New England Journal of Medicine 384 (22), 2161-2163, 2021 | 170* | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised … SA Madhi, AL Koen, A Izu, L Fairlie, CL Cutland, V Baillie, ... The Lancet HIV 8 (9), e568-e580, 2021 | 148 | 2021 |
| Prior infection with SARS-CoV-2 boosts and broadens Ad26. COV2. S immunogenicity in a variant-dependent manner R Keeton, SI Richardson, T Moyo-Gwete, T Hermanus, MB Tincho, ... Cell host & microbe 29 (11), 1611-1619. e5, 2021 | 114 | 2021 |
| SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals SI Richardson, VS Madzorera, H Spencer, NP Manamela, ... Cell Host & Microbe 30 (6), 880-886. e4, 2022 | 109 | 2022 |
| Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity C Riou, R Keeton, T Moyo-Gwete, T Hermanus, P Kgagudi, R Baguma, ... Science translational medicine 14 (631), eabj6824, 2021 | 104 | 2021 |
| Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant DK Ryu, R Song, M Kim, YI Kim, C Kim, JI Kim, KS Kwon, ASL Tijsma, ... Biochemical and biophysical research communications 566, 135-140, 2021 | 62 | 2021 |
| SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021 J Mandolo, J Msefula, MYR Henrion, C Brown, B Moyo, A Samon, ... BMC medicine 19, 1-10, 2021 | 54 | 2021 |
| Anti-V3/glycan and anti-MPER neutralizing antibodies, but not anti-V2/glycan site antibodies, are strongly associated with greater anti-HIV-1 neutralization breadth and potency RA Jacob, T Moyo, M Schomaker, F Abrahams, B Grau Pujol, JR Dorfman Journal of virology 89 (10), 5264-5275, 2015 | 42 | 2015 |
| Ad26. COV2. S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern D Kitchin, SI Richardson, MA van der Mescht, T Motlou, N Mzindle, ... Cell Reports Medicine 3 (3), 2022 | 38* | 2022 |
| Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial) K van den Berg, TN Glatt, M Vermeulen, F Little, R Swanevelder, C Barrett, ... Scientific reports 12 (1), 2552, 2022 | 28 | 2022 |
| Antibody isotype switching as a mechanism to counter HIV neutralization escape C Scheepers, V Bekker, C Anthony, SI Richardson, B Oosthuysen, T Moyo, ... Cell reports 33 (8), 2020 | 23 | 2020 |
| AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2 MG Chibwana, T Moyo-Gwete, G Kwatra, J Mandolo, T Hermanaus, ... BMC medicine 20 (1), 128, 2022 | 22 | 2022 |
| Structural rearrangements maintain the glycan shield of an HIV-1 envelope trimer after the loss of a glycan RC Ferreira, OC Grant, T Moyo, JR Dorfman, RJ Woods, SA Travers, ... Scientific reports 8 (1), 15031, 2018 | 22 | 2018 |
| Neutralizing antibodies elicited by the Ad26. COV2. S COVID-19 vaccine show reduced activity against 501Y. V2 (B. 1.351), despite protection against severe disease by this variant PL Moore, T Moyo-Gwete, T Hermanus, P Kgagudi, F Ayres, Z Makhado, ... BioRxiv, 2021.06. 09.447722, 2021 | 19 | 2021 |
| Targeting the N332-supersite of the HIV-1 envelope for vaccine design T Moyo, D Kitchin, PL Moore Expert opinion on therapeutic targets 24 (6), 499-509, 2020 | 18 | 2020 |
| Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11 T Moyo, J Ereño-Orbea, RA Jacob, CE Pavillet, SM Kariuki, EN Tangie, ... Journal of Virology 92 (14), 10.1128/jvi. 02261-17, 2018 | 18 | 2018 |
| Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies T Moyo, RC Ferreira, R Davids, Z Sonday, PL Moore, SA Travers, ... Virology 501, 12-24, 2017 | 18 | 2017 |